Aprea Therapeutics (NASDAQ:APRE) Earns Outperform Rating from Wedbush

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $11.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 391.07% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Aprea Therapeutics Price Performance

Shares of Aprea Therapeutics stock opened at $2.24 on Tuesday. The firm has a market cap of $12.17 million, a P/E ratio of -0.80 and a beta of 0.82. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $6.80. The firm has a 50 day simple moving average of $3.10 and a 200 day simple moving average of $3.25.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.20. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.15 million. On average, sell-side analysts expect that Aprea Therapeutics will post -2.55 EPS for the current year.

Institutional Investors Weigh In On Aprea Therapeutics

A number of institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in shares of Aprea Therapeutics in the fourth quarter valued at approximately $43,000. LPL Financial LLC acquired a new position in Aprea Therapeutics in the 4th quarter valued at $53,000. Landscape Capital Management L.L.C. bought a new stake in shares of Aprea Therapeutics during the 4th quarter valued at $116,000. Finally, Stonepine Capital Management LLC grew its holdings in shares of Aprea Therapeutics by 8.8% during the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after purchasing an additional 12,047 shares in the last quarter. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.